Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 119; no. 9; p. 1
• Main Authors: Singh, Ranjan K, Soliman, Ahmed, Guaitoli, Giambattista, Störmer, Eliza, von Zweydorf, Felix, Dal Maso, Thomas, Oun, Asmaa, Van Rillaer, Laura, Schmidt, Sven H, Chatterjee, Deep, David, Joshua A, Pardon, Els, Schwartz, Thomas U, Knapp, Stefan, Kennedy, Eileen J, Steyaert, Jan, Herberg, Friedrich W, Kortholt, Arjan, Gloeckner, Christian Johannes, Versées, Wim
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 01.03.2022
• Subjects: Allosteric properties; ATP; Binding; Biological Sciences; Drug development; Inhibitors; Kinases; Leucine; LRRK2 protein; Modulators; Movement disorders; Mutation; Nanobodies; Neurodegenerative diseases; Parkinson's disease; Phosphorylation; Protein kinase; Proteins; Rab protein; Substrate inhibition; nanobody; allosteric inhibitor; drug design; LRRK2; Parkinson’s disease
• ISSN: 0027-8424; 1091-6490; 1091-6490
• DOI: 10.1073/pnas.2112712119

Mutations in the gene coding for leucine-rich repeat kinase 2 (LRRK2) are a leading cause of the inherited form of Parkinson's disease (PD), while LRRK2 overactivation is also associated with the more common idiopathic form of PD. LRRK2 is a large multidomain protein, including a GTPase as well as a Ser/Thr protein kinase domain. Common, disease-causing mutations increase LRRK2 kinase activity, presenting LRRK2 as an attractive target for drug discovery. Currently, drug development has mainly focused on ATP-competitive kinase inhibitors. Here, we report the identification and characterization of a variety of nanobodies that bind to different LRRK2 domains and inhibit or activate LRRK2 in cells and in in vitro. Importantly, nanobodies were identified that inhibit LRRK2 kinase activity while binding to a site that is topographically distinct from the active site and thus act through an allosteric inhibitory mechanism that does not involve binding to the ATP pocket or even to the kinase domain. Moreover, while certain nanobodies completely inhibit the LRRK2 kinase activity, we also identified nanobodies that specifically inhibit the phosphorylation of Rab protein substrates. Finally, in contrast to current type I kinase inhibitors, the studied kinase-inhibitory nanobodies did not induce LRRK2 microtubule association. These comprehensively characterized nanobodies represent versatile tools to study the LRRK2 function and mechanism and can pave the way toward novel diagnostic and therapeutic strategies for PD.